Results Of The Randomized, Placebo (Pl)-Controlled Phase Ii Study Evaluating The Efficacy And Safety Of Regorafenib (Reg) In Patients (Pts) With Metastatic Relapsed Ewing Sarcoma (Es), On Behalf Of The French Sarcoma Group (Fsg) And Unicancer